ARDELYX, INC. Selling, General and Administrative Expense
ARDELYX, INC. (ARDX) reported Selling, General and Administrative Expense of $101.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- ARDELYX, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $101.44M, a 20.78% increase year-over-year.
- ARDELYX, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $102.27M, a 22.88% increase year-over-year.
- ARDELYX, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $86.41M, a 13.59% increase year-over-year.
- ARDELYX, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $83.61M, a 28.69% increase year-over-year.
- ARDELYX, INC. selling, general and administrative expense for fiscal 2025 was $337.23M, a 30.36% increase from fiscal 2024.
- ARDELYX, INC. selling, general and administrative expense for fiscal 2024 was $258.69M, a 92.48% increase from fiscal 2023.
- ARDELYX, INC. selling, general and administrative expense for fiscal 2023 was $134.40M, a 75.46% increase from fiscal 2022.
- ARDELYX, INC. selling, general and administrative expense for fiscal 2022 was $76.60M, a 5.94% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $101.44M 10-Q · filed 2026-08-06 | $203.71M 10-Q · filed 2026-08-06 | $290.12M derived: sum of 3 quarters · filed 2026-08-06 | $373.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $102.27M 10-Q · filed 2026-04-30 | $188.68M derived: sum of 2 quarters · filed 2026-04-30 | $272.29M derived: sum of 3 quarters · filed 2026-04-30 | $356.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $86.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $170.02M derived: sum of 2 quarters · filed 2026-02-19 | $254.01M derived: sum of 3 quarters · filed 2026-08-06 | $337.23M 10-K · filed 2026-02-19 |
| 2025-09-30 | $83.61M 10-Q · filed 2025-10-30 | $167.60M derived: sum of 2 quarters · filed 2026-08-06 | $250.82M 10-Q · filed 2025-10-30 | $326.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $83.99M 10-Q · filed 2026-08-06 | $167.21M 10-Q · filed 2026-08-06 | $243.28M derived: sum of 3 quarters · filed 2026-08-06 | $308.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $83.22M 10-Q · filed 2026-04-30 | $159.30M derived: sum of 2 quarters · filed 2026-04-30 | $224.27M derived: sum of 3 quarters · filed 2026-04-30 | $288.92M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $76.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $141.04M derived: sum of 2 quarters · filed 2026-02-19 | $205.70M derived: sum of 3 quarters · filed 2026-02-19 | $258.69M 10-K · filed 2026-02-19 |
| 2024-09-30 | $64.97M 10-Q · filed 2025-10-30 | $129.62M derived: sum of 2 quarters · filed 2025-10-30 | $182.62M 10-Q · filed 2025-10-30 | $230.37M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $64.65M 10-Q · filed 2025-08-04 | $117.65M 10-Q · filed 2025-08-04 | $165.40M derived: sum of 3 quarters · filed 2026-02-19 | $198.06M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $52.99M 10-Q · filed 2025-05-01 | $100.74M derived: sum of 2 quarters · filed 2026-02-19 | $133.41M derived: sum of 3 quarters · filed 2026-02-19 | $160.59M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $47.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $80.41M derived: sum of 2 quarters · filed 2026-02-19 | $107.60M derived: sum of 3 quarters · filed 2026-02-19 | $134.40M 10-K · filed 2026-02-19 |
| 2023-09-30 | $32.66M 10-Q · filed 2024-10-31 | $59.85M derived: sum of 2 quarters · filed 2024-10-31 | $86.65M 10-Q · filed 2024-10-31 | $106.38M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $27.19M 10-Q · filed 2024-08-01 | $53.99M 10-Q · filed 2024-08-01 | $73.72M derived: sum of 3 quarters · filed 2025-02-20 | $92.39M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $26.80M 10-Q · filed 2024-05-02 | $46.53M derived: sum of 2 quarters · filed 2025-02-20 | $65.20M derived: sum of 3 quarters · filed 2025-02-20 | $84.06M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $38.40M derived: sum of 2 quarters · filed 2025-02-20 | $57.26M derived: sum of 3 quarters · filed 2025-02-20 | $76.60M 10-K · filed 2025-02-20 |
| 2022-09-30 | $18.67M 10-Q · filed 2023-10-31 | $37.53M derived: sum of 2 quarters · filed 2023-10-31 | $56.87M 10-Q · filed 2023-10-31 | $72.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $18.86M 10-Q · filed 2023-08-02 | $38.20M 10-Q · filed 2023-08-02 | $53.53M derived: sum of 3 quarters · filed 2024-02-22 | $73.25M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $19.34M 10-Q · filed 2023-05-03 | $34.67M derived: sum of 2 quarters · filed 2024-02-22 | $54.39M derived: sum of 3 quarters · filed 2024-02-22 | $74.51M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $35.05M derived: sum of 2 quarters · filed 2024-02-22 | $55.17M derived: sum of 3 quarters · filed 2024-02-22 | $72.30M 10-K · filed 2024-02-22 |
| 2021-09-30 | $19.71M 10-Q · filed 2022-11-03 | $39.84M derived: sum of 2 quarters · filed 2022-11-03 | $56.97M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $20.12M 10-Q · filed 2022-08-04 | $37.26M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $17.13M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |